Cynata Therapeutics Limited
CYYNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $27 | $57 | $51 | $19 |
| - Cash | $5 | $11 | $6 | $11 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $22 | $46 | $45 | $8 |
| Revenue | -$0 | $2 | -$0 | $3 |
| % Growth | -104.3% | 956.3% | -109% | – |
| Gross Profit | -$0 | $2 | -$0 | $1 |
| % Margin | 100% | 100% | 100% | 44.5% |
| EBITDA | -$6 | -$4 | -$6 | -$7 |
| % Margin | 6,842.2% | -178.3% | 2,411.9% | -272.9% |
| Net Income | -$6 | -$4 | -$5 | -$5 |
| % Margin | 6,755.1% | -185.3% | 2,261.8% | -178.4% |
| EPS Diluted | -0.025 | -0.02 | -0.029 | -0.025 |
| % Growth | -28.3% | 31.7% | -14.6% | – |
| Operating Cash Flow | -$6 | -$3 | -$5 | -$5 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$6 | -$3 | -$5 | -$5 |